141 related articles for article (PubMed ID: 23884775)
1. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma.
Hescot S; Leboulleux S; Amar L; Vezzosi D; Borget I; Bournaud-Salinas C; de la Fouchardiere C; Libé R; Do Cao C; Niccoli P; Tabarin A; Raingeard I; Chougnet C; Giraud S; Gimenez-Roqueplo AP; Young J; Borson-Chazot F; Bertherat J; Wemeau JL; Bertagna X; Plouin PF; Schlumberger M; Baudin E;
J Clin Endocrinol Metab; 2013 Oct; 98(10):4006-12. PubMed ID: 23884775
[TBL] [Abstract][Full Text] [Related]
2. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
[TBL] [Abstract][Full Text] [Related]
3. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study.
Hescot S; Curras-Freixes M; Deutschbein T; van Berkel A; Vezzosi D; Amar L; de la Fouchardière C; Valdes N; Riccardi F; Do Cao C; Bertherat J; Goichot B; Beuschlein F; Drui D; Canu L; Niccoli P; Laboureau S; Tabarin A; Leboulleux S; Calsina B; Libé R; Faggiano A; Schlumberger M; Borson-Chazot F; Mannelli M; Gimenez-Roqueplo AP; Caron P; Timmers HJLM; Fassnacht M; Robledo M; Borget I; Baudin E;
J Clin Endocrinol Metab; 2019 Jun; 104(6):2367-2374. PubMed ID: 30715419
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
Oh DY; Kim TW; Park YS; Shin SJ; Shin SH; Song EK; Lee HJ; Lee KW; Bang YJ
Cancer; 2012 Dec; 118(24):6162-70. PubMed ID: 22736481
[TBL] [Abstract][Full Text] [Related]
7. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
[TBL] [Abstract][Full Text] [Related]
8. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
Amar L; Baudin E; Burnichon N; Peyrard S; Silvera S; Bertherat J; Bertagna X; Schlumberger M; Jeunemaitre X; Gimenez-Roqueplo AP; Plouin PF
J Clin Endocrinol Metab; 2007 Oct; 92(10):3822-8. PubMed ID: 17652212
[TBL] [Abstract][Full Text] [Related]
9. Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience.
Choi YM; Sung TY; Kim WG; Lee JJ; Ryu JS; Kim TY; Kim WB; Hong SJ; Song DE; Shong YK
J Surg Oncol; 2015 Dec; 112(8):815-21. PubMed ID: 26464058
[TBL] [Abstract][Full Text] [Related]
10. Paraganglioma: not just an extra-adrenal pheochromocytoma.
Laird AM; Gauger PG; Doherty GM; Miller BS
Langenbecks Arch Surg; 2012 Feb; 397(2):247-53. PubMed ID: 22086065
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of a large series of patients surgically treated for pheochromocytoma.
Khorram-Manesh A; Ahlman H; Nilsson O; Friberg P; Odén A; Stenström G; Hansson G; Stenquist O; Wängberg B; Tisell LE; Jansson S
J Intern Med; 2005 Jul; 258(1):55-66. PubMed ID: 15953133
[TBL] [Abstract][Full Text] [Related]
12. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
[TBL] [Abstract][Full Text] [Related]
13. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma.
Ayala-Ramirez M; Palmer JL; Hofmann MC; de la Cruz M; Moon BS; Waguespack SG; Habra MA; Jimenez C
J Clin Endocrinol Metab; 2013 Apr; 98(4):1492-7. PubMed ID: 23436918
[TBL] [Abstract][Full Text] [Related]
14. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
[TBL] [Abstract][Full Text] [Related]
15. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience.
Shilkrut M; Bar-Deroma R; Bar-Sela G; Berniger A; Kuten A
Am J Clin Oncol; 2010 Feb; 33(1):79-82. PubMed ID: 19704370
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric DNA analysis for determination of malignant potential in adrenal pheochromocytoma or paraganglioma: an Indian experience.
Shah MJ; Karelia NH; Patel SM; Desai NS; Mehta HV; Singh S
Ann Surg Oncol; 2003 May; 10(4):426-31. PubMed ID: 12734092
[TBL] [Abstract][Full Text] [Related]
17. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy.
McBride JF; Atwell TD; Charboneau WJ; Young WF; Wass TC; Callstrom MR
J Vasc Interv Radiol; 2011 Sep; 22(9):1263-70. PubMed ID: 21856504
[TBL] [Abstract][Full Text] [Related]
18. Prognostic profile for patients with pheochromocytoma derived from clinical and pathological factors and DNA ploidy pattern.
Nativ O; Grant CS; Sheps SG; O'Fallon JR; Farrow GM; van Heerden JA; Lieber MM
J Surg Oncol; 1992 Aug; 50(4):258-62. PubMed ID: 1640712
[TBL] [Abstract][Full Text] [Related]
19. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
[TBL] [Abstract][Full Text] [Related]
20. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma.
Timmers HJ; Brouwers FM; Hermus AR; Sweep FC; Verhofstad AA; Verbeek AL; Pacak K; Lenders JW
Endocr Relat Cancer; 2008 Dec; 15(4):1127-33. PubMed ID: 18824558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
